Thursday, 27 January 2022

Australia's most trusted
source of pharma news

Thursday, 27 January 2022

Drug class contamination fear

Posted 9 December 2021 AM

The TGA has said it is investigating potential contamination of rifampicin antibiotics in Australia, after sponsors of the products, Sanofi and Alphapharm, reported that all products circulating in the market contain traces of 1-methyl-5-nitrosopiperazine (MeNP).

Sanofi's Rifadin and Alphapharm's Rimycin are essential, first-line medicines for the treatment of tuberculosis and are also used to treat or prevent other serious infections including blood infections and leprosy.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.